Search - tctmd.com

Displaying 241 - 253 of 253

Sort: Relevancy | Date

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

News Daily News

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

Michael O'Riordan

June 30, 2016

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

Presentation

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

Presenter: BM. Everett BM

August 14, 2015

News Daily News

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

Yael L. Maxwell

August 12, 2015

News Daily News

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Yael L. Maxwell

August 12, 2015

Presentation

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

Presenter: Vera Bittner

August 11, 2015

Presentation

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

Presenter: Mohamed Abdel-Wahab

July 23, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Conference News AHA 2012

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Jason Kahn

November 11, 2012

Advertisement

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

FDA Advisory Panel Narrowly Recommends CVD Mortality Indication for Diabetes Drug Empagliflozin

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes

BARI 2D: Increased Risk Factor Control in Patients With Type 2 Diabetes Ups Survival

BARI 2D: El Mayor Control de los Factores de Riesgo en Pacientes con Diabetes Tipo 2 Mejora Supervivencia

BARI 2D：改善 2 型糖尿病患者的危险因素控制情况可以提高其生存率

Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

AHA 2012: Multiple Studies Provide Clinical Guidance for Interventional Community

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content